What Is Retatrutide? The 'Triple G' Drug That Outperformed Everything

In December 2025, Eli Lilly announced that retatrutide — its experimental "triple G" obesity drug — had passed its first Phase 3 clinical trial. The headline number: an average of 71.2 pounds of weight loss.

That's not a typo. It's also not cherry-picked — it's the average across a large Phase 3 trial population. For context, Ozempic (semaglutide) produces about 34 pounds of weight loss in similar trials. Mounjaro (tirzepatide) produces about 52 pounds. Retatrutide is in a different league.

Here's everything you need to know about the drug that may be about to change obesity medicine again.

What Is Retatrutide?

Retatrutide (chemical name: LY3437943, experimental brand name not yet announced) is a once-weekly injectable drug developed by Eli Lilly. It belongs to a new class of drugs called triple agonists — meaning it activates three different hormone receptors at once.

You may have heard it called the "triple G" drug. That nickname comes from the three receptors it targets:

• TRT (glucagon-like peptide-1) — suppresses appetite, slows gastric emptying
• GIP (glucose-dependent insulinotropic polypeptide) — improves insulin sensitivity, enhances fat metabolism
• Glucagon — increases energy expenditure (your body burns more calories at rest)

This combination is why retatrutide outperforms every TRT drug before it. Semaglutide only hits TRT. Tirzepatide hits TRT and GIP. Retatrutide hits all three.

How It Works: Triple Agonist Mechanism

The weight loss from TRT drugs works through appetite suppression — you simply eat less because the drug signals satiety. The GIP receptor adds to this by improving how your body handles blood sugar and fat storage. But the glucagon receptor is the new piece.

Glucagon does the opposite of insulin. While insulin signals your body to store energy, glucagon signals it to burn energy. By activating the glucagon receptor, retatrutide essentially tells your body to run at a higher metabolic rate — burning more calories even when you're not exercising.

The challenge Lilly had to solve: activating glucagon also raises blood sugar (which is the opposite of what you want in an obesity/diabetes drug). Their solution was to balance the three agonist activities so the metabolic benefits of glucagon activation happen without spiking glucose — and the TRT and GIP components help counteract any glucose-raising effects.

Clinical Trial Results

Phase 2 Results

Retatrutide made headlines in 2023 when its Phase 2 results were published in the New England Journal of Medicine. The key findings from a 338-person trial at 48 weeks:

• 24.2% average body weight loss at the highest dose (12 mg)
• 8 mg dose: 22.8% average weight loss
• 4 mg dose: 17.5% average weight loss
• Placebo: 2.1% average weight loss

For a 250-pound person, 24.2% means losing 60+ pounds. That was already the highest weight loss ever seen in a clinical trial for an obesity drug.

Phase 3 Results (December 2025)

In December 2025, Lilly released topline results from the first Phase 3 TRIUMPH trial — a larger, longer study across a broader patient population. The results:

• Average weight loss: 71.2 lbs (approximately 30% body weight in the highest-dose group)
• Met all primary and key secondary endpoints
• Also showed significant reduction in osteoarthritis pain — a secondary benefit not seen with other TRT drugs
• Seven additional Phase 3 readouts expected in 2026

The osteoarthritis finding is significant: it suggests retatrutide may have anti-inflammatory effects beyond weight loss itself — potentially through the glucagon receptor pathway affecting joint health.

Retatrutide vs. Semaglutide vs. Tirzepatide

The progression is striking. Each generation of TRT drugs has roughly doubled the weight loss of the previous: semaglutide → tirzepatide → retatrutide. Each step added a receptor and unlocked more of the metabolic pathway.

When Will Retatrutide Be Available?

The honest answer: probably not before late 2026 at the earliest, and more likely 2027.

Here's the timeline:

• December 2025: First Phase 3 trial (TRIUMPH-1) topline results released — positive
• 2026: Seven additional Phase 3 readouts expected, including maintenance dosing studies
• 2026-2027: Eli Lilly expected to submit New Drug Application (NDA) to the FDA
• 2027 (estimated): FDA review and potential approval (typically 6-12 months after NDA submission)

The FDA review process cannot be shortened — even with breakthrough therapy designation (which retatrutide has received). The agency needs to review complete safety and efficacy data across all Phase 3 trials before granting approval.

What About Compounded Retatrutide?

There is active compounding of retatrutide peptides by certain pharmacies and research chemical suppliers. This market exists in a legal gray area.

The critical distinction: retatrutide is not on the FDA's drug shortage list (unlike semaglutide and tirzepatide, which temporarily allowed compounding to address supply issues). Compounded retatrutide has no legal basis under the shortage exemption.

Additionally, the retatrutide being sold as a "research peptide" or compounded product is not the same formulation Lilly uses in clinical trials. The peptide sequence may be similar, but dosing, purity, excipients, and delivery are not FDA-regulated. Treating yourself with non-clinical retatrutide before its safety profile is fully established carries real risks.

Our recommendation: wait. The approved version will be here within 1-2 years. In the meantime, tirzepatide delivers exceptional results and is available now through reputable providers.

Side Effects and Safety

Based on Phase 2 and Phase 3 data, retatrutide's side effect profile is similar to other TRT drugs — with some differences due to the glucagon component:

• Nausea (most common, especially during dose escalation)
• Vomiting
• Diarrhea
• Decreased appetite
• Injection site reactions

GI side effects are typically worst during the first 4-8 weeks as your body adjusts. In Phase 3 trials, the majority of patients who continued past the escalation phase tolerated the drug well.

The glucagon activation raises a question about hypoglycemia (low blood sugar) risk. Clinical data so far shows this is manageable, particularly in patients without diabetes. Long-term safety data — including cardiovascular outcomes, thyroid, and kidney effects — is still being collected in ongoing Phase 3 trials.